Veradermics, Incorporated (NYSE: MANE)

A tiny dermatology company out of New Haven picked the ticker MANE. That turned out to be the least surprising thing about its year. Here’s who Veradermics is, what they’re building, how far along they are, and roughly when their drug might show up on a pharmacy shelf.

The Story So Far

Two dermatologists, Reid Waldman and Ming Lee, founded Veradermics in 2019 in New Haven, Connecticut. For years the company operated quietly as a private biotech. It raised money through several funding rounds, including a $75 million Series B and an oversubscribed $150 million Series C led by SR One, to push its lead drug candidate through clinical trials.

Veradermics went public on February 4, 2026. It priced its IPO at $17 a share and raised roughly $256 million, later closer to $295 million once underwriters exercised their full option. Shares more than doubled on the first day of trading, closing near $37.75. Investor enthusiasm never really let up after that. By July the stock had climbed over 650% from its debut. By late summer it traded somewhere in the high double digits to low triple digits depending on the week, giving the company a market cap north of $2 billion. It still has zero approved products and zero revenue.

That’s the classic biotech arc: dermatologists with a scientific idea, years of private funding, a splashy IPO, and a stock price that now lives and dies with every clinical trial readout.

What They Actually Do

Veradermics calls itself a dermatologist founded, late stage biopharmaceutical company focused on aesthetic and dermatologic conditions. In plain English, they build drugs for common skin and hair problems that don’t have great treatment options yet. Their pipeline includes:

• VDPHL01, their lead program and by far the most important asset, aimed at pattern hair loss in both men and women
• VDMN, a dissolvable microarray patch that uses the immune system to treat common warts
• VDAA, an early stage candidate for alopecia areata, an autoimmune condition that causes patchy hair loss
• VDMC, a candidate for molluscum contagiosum, a viral skin infection that mostly affects children

Everything besides VDPHL01 is still early stage. The company’s near term valuation rides almost entirely on this one drug.

The Product: VDPHL01

VDPHL01 is an oral, extended release tablet built around minoxidil. That’s the same active ingredient found in Rogaine and in the topical foams people already use for hair loss. Minoxidil itself isn’t new. Veradermics is trying to fix how it gets delivered.

Some dermatologists already prescribe oral minoxidil off label. They use a pill originally designed decades ago to treat high blood pressure. That immediate release formulation can spike blood plasma levels quickly, which raises the risk of cardiac side effects. That risk is a big reason it never got formally approved for hair loss.

Veradermics built a different formulation instead. It uses a gel matrix that releases minoxidil slowly and steadily over time. The goal is to avoid the sharp peak concentrations that cause heart related side effects, while keeping minoxidil levels above the threshold needed for hair growth for longer.

If regulators approve it, VDPHL01 would become the first FDA approved oral, non hormonal treatment for pattern hair loss. Nothing like it has reached approval in almost three decades. That matters because current prescription options, like finasteride, work by altering hormone levels. Those drugs come with side effects that turn a lot of patients away.

How Far Along Are They?

This is where things get genuinely interesting for a company this young on the public markets. Pattern hair loss affects an estimated 80 million people in the United States, about 50 million men and 30 million women. No new FDA approved prescription drug has reached this market in roughly 30 years. It’s a big, underserved space, and Veradermics has made real clinical progress toward it.

The Male Program

Here’s where things stand as of this writing:

• Study 302, a Phase 2/3 trial in 519 men with mild to moderate pattern hair loss, reported positive topline results in April 2026. The trial hit every primary and key secondary endpoint with strong statistical significance. Patients showed meaningful hair growth as early as month two. The safety profile looked similar to placebo, with no serious drug related side effects and no cardiac related concerns.
• Study 304, a second confirmatory Phase 3 trial in roughly 536 men, finished enrollment earlier this year. That brings total male enrollment across both trials to nearly 1,000 patients. Topline results are expected in the second half of 2026.

The Female Program

Veradermics is also running a separate Phase 2/3 trial in women, Study 306. An earlier open label Phase 2 study in women, Study 207, reported positive results over the summer too. The female program follows its own regulatory timeline and sits a bit further behind the male one.

The Balance Sheet

Veradermics isn’t shy about spending. The company raised more capital through a follow on offering in May 2026, bringing in over $400 million, plus a private warrant sale. By mid 2026 it held close to $820 million in cash and short term investments, against a net loss of roughly $50 million for the first half of the year. That gives Veradermics plenty of runway to finish these trials and prepare a regulatory filing without needing to raise money again soon. Spending could accelerate, though, so that runway isn’t fixed in stone.

How Long Until It’s Actually For Sale?

Every investor and every hopeful future customer wants to know this. The honest answer: not particularly soon, though the path is coming into view.

Assuming Study 304 confirms what Study 302 already showed, Veradermics plans to file a New Drug Application with the FDA in early 2027. A standard FDA review takes about ten months. A priority review, if granted, can take closer to six. Put together, most analysts following the stock point to a realistic launch window between late 2027 and mid 2028 for the male indication, assuming everything goes smoothly. The female indication, tied to its own separate trial, will likely trail behind that.

None of this is guaranteed. Confirmatory trials sometimes fail to replicate earlier results. The FDA can ask for more data. Manufacturing or labeling issues can push timelines out further. Still, compared to most clinical stage biotechs, Veradermics sits genuinely close by industry standards. This isn’t a drug still trying to prove it does anything. It’s a drug trying to confirm what it already showed once, in front of a regulator that has approved this exact molecule, just not this formulation, for decades.

The Bottom Line for Anyone Watching the Stock

Veradermics tells one of those rare biotech stories where the market opportunity is enormous, the underlying science isn’t some brand new unproven mechanism, and the clinical data so far has come back clean. That combination explains a lot of why the stock ran the way it did after its IPO. At the same time, everything still hinges on one confirmatory trial due later this year and an FDA process that hasn’t started yet. Until Study 304 reads out and an NDA actually gets filed, this remains, like every clinical stage biotech, a bet on a molecule that isn’t approved yet and isn’t earning a single dollar of revenue.

Readers who like watching binary catalysts play out in real time may want to keep this name on a watchlist through the second half of 2026.

Source: Veradermics

Disclosure: The author has no position in $MANE and no commercial relationship with the company